| MDL | MFCD23381190 |
|---|---|
| Molecular Weight | 501.49 |
| Molecular Formula | C20H31N5O10 |
| SMILES | O=C(ON1C(CCC1=O)=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2 |
DOTA-NHS-ester can be used to modify human serum albumin (HSA) to produce DOTA-HSA. And DOTA-HSA is furtherly modified by Sulfo-SMCC (HY-D0975) to obtain DOTA-HSA-SMCC. DOTA-HSA-SMCC is conjugated to ZHER2:342 and the final product is DOTA-HSA-Z
HER2
:342
[1]
.
In a cell uptake assay, DOTA-HSA-Z
HER2
:342
is labeled by
64
Cu,
64
Cu-DOTA-HSA-Z
HER2
:342
(0.5-2 hours) slowly accumulates in the SKOV3 cells and reaches 0.71% of the applied activity at 0.5 h and the uptake increased to 1.58% at 2 h
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In a microPET images of a mouse bearing SKOV3 tumor,
64
Cu-DOTA-HSA-Z
HER2
:342
is injected to the mouse tail. microPET images of a mouse bearing SKOV3 tumor at 1, 4, 24 and 48 h after tail vein injection.
The SKOV3 tumor is visible with a low tumor-to-background contrast at 1 h post-injection (p.i.), but with a very good tumor-to-background contrast at 4 and 24 h p.i.
Quantification analysis reveals that the SKOV3 tumor uptake values increases with time and are found to be 5.63%, 9.98%, 14.34% and 14.12% ID/g at 1, 4, 24, and 48 h, respectively
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 50 mg/mL ( 99.70 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9941 mL | 9.9703 mL | 19.9406 mL |
| 5 mM | 0.3988 mL | 1.9941 mL | 3.9881 mL |
| 10 mM | 0.1994 mL | 0.9970 mL | 1.9941 mL |